As a knowledge-based pharmaceutical company, Nitka is focused on improving patients' lives by identifying, developing and commercializing new products. Our main goal is to produce products based on hyaluronic acid molecule for non-invasive orthopedic treatments.
As part of its ongoing commitment to improving patients' lives, Nitka is committed to producing products in a variety of therapeutic fields. This realization is possible by improving the sales quality of the company's current products and focusing on development in various fields of treatment.
At Nitka, we have embedded a culture of patient satisfaction that all our personnel strongly believe in and always follow. This is possible by defining the company's mission, vision and values. Each member of Nitka team strives to achieve this important goal of improving patients' lives.
2009 Establishment of the company
2010 Design of business model
2010 Formation of research team
2013 Completion of Synogel 1.5%
2014 Successful completion of industrial production
2015 Establishment of international cooperation for the production of a contract with the Italian company Savio
2015 Obtaining a production license of Synogel 1.5% from the Food and Drug Administration
2016 Production of Synogel 1.5% in Savio
2017 Supply of Synogel 1.5% to the pharmaceutical market of Iran country
2017 Obtaining a production license of Synogel 1.6% and Viscor 2%
2018 Supply of Synogel 1.6% and Viscor 2% to the pharmaceutical market of Iran country
Nitka's goal is to focus on three important subjects:
Patient satisfaction, efforts to improve patients' lives
Creating a suitable environment for work
Centering Nitka values; Cooperation, honesty, passion for work and innovation